Latest Insider Transactions at Biomarin Pharmaceutical Inc (BMRN)
This section provides a real-time view of insider transactions for Biomarin Pharmaceutical Inc (BMRN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BIOMARIN PHARMACEUTICAL INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BIOMARIN PHARMACEUTICAL INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 16
2021
|
Henry J Fuchs President, Worldwide R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
2,259
-2.04%
|
$173,943
$77.21 P/Share
|
|
Mar 16
2021
|
George Eric Davis EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,252
-1.76%
|
$96,404
$77.21 P/Share
|
|
Mar 16
2021
|
Brian Mueller EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
582
-1.54%
|
$44,814
$77.21 P/Share
|
|
Mar 15
2021
|
Andrea Acosta GVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
553
-2.9%
|
$43,134
$78.39 P/Share
|
|
Mar 15
2021
|
Andrea Acosta GVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,290
+18.37%
|
-
|
|
Mar 15
2021
|
Jean Jacques Bienaime Director |
SELL
Payment of exercise price or tax liability
|
Direct |
23,426
-6.95%
|
$1,827,228
$78.39 P/Share
|
|
Mar 15
2021
|
Jean Jacques Bienaime Director |
BUY
Grant, award, or other acquisition
|
Direct |
41,350
+10.93%
|
-
|
|
Mar 15
2021
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,273
-7.32%
|
$411,294
$78.39 P/Share
|
|
Mar 15
2021
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,720
+12.96%
|
-
|
|
Mar 15
2021
|
Henry J Fuchs President, Worldwide R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
7,460
-6.31%
|
$581,880
$78.39 P/Share
|
|
Mar 15
2021
|
Henry J Fuchs President, Worldwide R&D |
BUY
Grant, award, or other acquisition
|
Direct |
15,320
+11.46%
|
-
|
|
Mar 15
2021
|
George Eric Davis EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,014
-6.59%
|
$391,092
$78.39 P/Share
|
|
Mar 15
2021
|
George Eric Davis EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,420
+12.04%
|
-
|
|
Mar 15
2021
|
Brian Mueller EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
994
-2.56%
|
$77,532
$78.39 P/Share
|
|
Mar 15
2021
|
Brian Mueller EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,110
+20.67%
|
-
|
|
Mar 15
2021
|
Charles Greg Guyer EVP, Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,420
+18.65%
|
-
|
|
Mar 12
2021
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
7,000
-2.31%
|
$539,000
$77.1 P/Share
|
|
Mar 12
2021
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+2.26%
|
$182,000
$26.49 P/Share
|
|
Mar 11
2021
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
7,000
-2.31%
|
$539,000
$77.68 P/Share
|
|
Mar 11
2021
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+2.26%
|
$182,000
$26.49 P/Share
|
|
Mar 05
2021
|
Michael G Grey Director |
SELL
Open market or private sale
|
Direct |
5,000
-10.45%
|
$380,000
$76.28 P/Share
|
|
Mar 05
2021
|
Michael G Grey Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+9.46%
|
$130,000
$26.49 P/Share
|
|
Mar 04
2021
|
Jean Jacques Bienaime Director |
BUY
Small Acquisition
|
Direct |
100
+0.03%
|
$7,700
$77.94 P/Share
|
|
Feb 19
2021
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
7,000
-2.31%
|
$581,000
$83.58 P/Share
|
|
Feb 19
2021
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+2.26%
|
$182,000
$26.49 P/Share
|
|
Feb 18
2021
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
7,000
-2.31%
|
$595,000
$85.08 P/Share
|
|
Feb 18
2021
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+2.26%
|
$182,000
$26.49 P/Share
|
|
Feb 17
2021
|
Maykin Ho Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,350
+50.0%
|
-
|
|
Feb 17
2021
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
8,000
-2.64%
|
$672,000
$84.54 P/Share
|
|
Feb 17
2021
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+2.57%
|
$208,000
$26.49 P/Share
|
|
Feb 16
2021
|
V Bryan Lawlis Director |
SELL
Open market or private sale
|
Direct |
7,500
-28.46%
|
$652,500
$87.41 P/Share
|
|
Feb 16
2021
|
V Bryan Lawlis Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+22.16%
|
$195,000
$26.49 P/Share
|
|
Feb 03
2021
|
Brian Mueller EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,071
-3.6%
|
$87,822
$82.82 P/Share
|
|
Jan 29
2021
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
8,334
-2.74%
|
$683,388
$82.67 P/Share
|
|
Jan 29
2021
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,334
+2.67%
|
$216,684
$26.49 P/Share
|
|
Jan 28
2021
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
8,333
-2.74%
|
$683,306
$82.91 P/Share
|
|
Jan 28
2021
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,333
+2.67%
|
$216,658
$26.49 P/Share
|
|
Jan 27
2021
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
8,333
-2.74%
|
$708,305
$85.49 P/Share
|
|
Jan 27
2021
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,333
+2.67%
|
$216,658
$26.49 P/Share
|
|
Dec 29
2020
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
1,500
-0.51%
|
$132,000
$88.18 P/Share
|
|
Dec 28
2020
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
1,500
-0.5%
|
$132,000
$88.77 P/Share
|
|
Oct 14
2020
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,121
-3.35%
|
$167,559
$79.91 P/Share
|
|
Oct 07
2020
|
Elaine J Heron Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+18.3%
|
$390,000
$26.49 P/Share
|
|
Jul 09
2020
|
Jean Jacques Bienaime Director |
SELL
Bona fide gift
|
Indirect |
425
-0.17%
|
-
|